Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
Each company listed discloses EW in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named EW in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Bernard Zovighian | $1,192,500 | $0 | $7,167,024 | $6,499,109 | $2,406,537 | $0 | $189,085 | $17,454,255 |
| Chief Executive Officer and Director | ||||||||
| Scott Ullem | 807,898 | 0 | 2,205,238 | 1,999,726 | 966,435 | 0 | 71,257 | 6,050,554 |
| Corporate Vice President, Chief Financial Officer | ||||||||
| Larry Wood | 635,919 | 0 | 1,818,499 | 1,648,710 | 689,382 | 0 | 61,829 | 4,854,339 |
| Former Corporate Vice President and Group President, Transcatheter Aortic Valve Replacement and Surgical Structural Heart | ||||||||
| Daveen Chopra | 671,042 | 0 | 1,764,066 | 1,375,784 | 824,239 | 0 | 60,611 | 4,695,742 |
| Corporate Vice President, Transcatheter Mitral and Tricuspid Therapies | ||||||||
| Donald Bobo | 759,783 | 0 | 1,378,274 | 1,249,829 | 786,899 | 0 | 48,580 | 4,223,365 |
| Corporate Vice President, Strategy & Corporate Development | ||||||||
| Annette Brüls | 726,586 | 0 | 1,020,334 | 924,995 | 719,581 | 158,905 | 181,706 | 3,732,107 |
| Corporate Vice President, EMEACLA | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Bernard Zovighian | $17,454,255 | $14,579,474 | $12,869,020 | +2,874,781 |
| Scott Ullem | 6,050,554 | 5,303,183 | 5,949,153 | +747,371 |
| Larry Wood | 4,854,339 | 4,608,661 | 5,395,034 | +245,678 |
| Daveen Chopra | 4,695,742 | 3,720,491 | — | +975,251 |
| Donald Bobo | 4,223,365 | — | — | — |
| Annette Brüls | 3,732,107 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Donald Bobo | CVP,Strategy/Corp Development | 2026-04-02 | D | 22,680 | $0 | $0 | Derivative, Class A Common | Form 4 ↗ |
| Donald Bobo | CVP,Strategy/Corp Development | 2026-04-02 | A | 22,680 | 59 | 1,343,942 | Common | Form 4 ↗ |
| Donald Bobo | CVP,Strategy/Corp Development | 2026-04-02 | D | 4,676 | 81 | 376,846 | Common, open-market sale | Form 4 ↗ |
| Donald Bobo | CVP,Strategy/Corp Development | 2026-04-02 | D | 18,004 | 80 | 1,441,209 | Common, open-market sale | Form 4 ↗ |
| Daniel J. Lippis | CVP, TAVR | 2026-04-06 | D | 1,019 | 81 | 82,523 | Common, open-market sale | Form 4 ↗ |
| Daniel J. Lippis | CVP, TAVR | 2026-04-06 | A | 1,019 | 59 | 60,383 | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-04-06 | — | 1,019 | — | — | 1 insider, 1 accrual row | ||
| Scott Ullem | CVP, Chief Financial Officer | 2026-04-09 | D | 4,676 | 80 | 376,401 | Common, open-market sale | Form 4 ↗ |
| Scott Ullem | CVP, Chief Financial Officer | 2026-04-09 | D | 13,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Scott Ullem | CVP, Chief Financial Officer | 2026-04-09 | A | 13,000 | 59 | 770,337 | Common | Form 4 ↗ |
| Scott Ullem | CVP, Chief Financial Officer | 2026-04-09 | D | 8,324 | 80 | 664,144 | Common, open-market sale | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-05-01 | — | 2,038 | — | — | 1 insider, 2 accrual rows | ||
| Daniel J. Lippis | CVP, TAVR | 2026-05-01 | A | 1,019 | 59 | 60,383 | Common | Form 4 ↗ |
| Daniel J. Lippis | CVP, TAVR | 2026-05-01 | D | 19 | 84 | 1,596 | Common, open-market sale | Form 4 ↗ |
| Daniel J. Lippis | CVP, TAVR | 2026-05-01 | D | 1,019 | 84 | 85,576 | Common | Form 4 ↗ |
| Daniel J. Lippis | CVP, TAVR | 2026-05-01 | D | 252 | 84 | 21,163 | Common | Form 4 ↗ |
| Daniel J. Lippis | CVP, TAVR | 2026-05-01 | D | 1,000 | 83 | 82,989 | Common, open-market sale | Form 4 ↗ |
| Daniel J. Lippis | CVP, TAVR | 2026-05-01 | A | 1,019 | 59 | 60,383 | Common | Form 4 ↗ |
| Donald Bobo | CVP,Strategy/Corp Development | 2026-05-03 | D | 469 | 84 | 39,387 | Common | Form 4 ↗ |
| Daveen Chopra | CVP, TMTT & Surgical | 2026-05-03 | D | 282 | 84 | 23,682 | Common | Form 4 ↗ |
| Scott Ullem | CVP, Chief Financial Officer | 2026-05-03 | A | 13,000 | 59 | 770,337 | Common | Form 4 ↗ |
| Bernard Zovighian | Director | 2026-05-03 | D | 523 | 0 | 0 | Common | Form 4 ↗ |
| Bernard Zovighian | Director | 2026-05-03 | A | 523 | 0 | 0 | Common | Form 4 ↗ |
| Scott Ullem | CVP, Chief Financial Officer | 2026-05-03 | D | 11,131 | 83 | 922,871 | Common | Form 4 ↗ |
| Scott Ullem | CVP, Chief Financial Officer | 2026-05-03 | D | 13,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Scott Ullem | CVP, Chief Financial Officer | 2026-05-03 | D | 620 | 84 | 52,068 | Common | Form 4 ↗ |
| Bernard Zovighian | Director | 2026-05-03 | D | 515 | 84 | 43,250 | Common | Form 4 ↗ |
| Daveen Chopra | CVP, TMTT & Surgical | 2026-05-07 | D | 674 | 83 | 56,077 | Common | Form 4 ↗ |
| Bernard Zovighian | Director | 2026-05-07 | D | 5,398 | 83 | 446,738 | Common | Form 4 ↗ |
| Wayne Markowitz | CVP, JAPAC | 2026-05-07 | A | 5,200 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Daniel J. Lippis | CVP, TAVR | 2026-05-07 | A | 39,900 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Daveen Chopra | CVP, TMTT & Surgical | 2026-05-07 | D | 1,141 | 83 | 94,429 | Common | Form 4 ↗ |
| Bernard Zovighian | Director | 2026-05-07 | A | 4,222 | 0 | 0 | Common | Form 4 ↗ |
| Donald Bobo | CVP,Strategy/Corp Development | 2026-05-07 | A | 7,850 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Scott Ullem | CVP, Chief Financial Officer | 2026-05-07 | D | 1,373 | 83 | 114,234 | Common | Form 4 ↗ |
| Donald Bobo | CVP,Strategy/Corp Development | 2026-05-07 | D | 1,038 | 83 | 85,905 | Common | Form 4 ↗ |
| Donald Bobo | CVP,Strategy/Corp Development | 2026-05-07 | A | 44,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Annette Bruls | CVP, EMEACLA | 2026-05-07 | A | 6,650 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Annette Bruls | CVP, EMEACLA | 2026-05-07 | A | 33,700 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Annette Bruls | CVP, EMEACLA | 2026-05-07 | D | 84 | 83 | 6,952 | Common | Form 4 ↗ |
| Annette Bruls | CVP, EMEACLA | 2026-05-07 | A | 6,650 | 0 | 0 | Common | Form 4 ↗ |
| Daveen Chopra | CVP, TMTT & Surgical | 2026-05-07 | A | 9,675 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Daveen Chopra | CVP, TMTT & Surgical | 2026-05-07 | A | 49,100 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Andrew M. Dahl | SVP, Corporate Controller | 2026-05-07 | D | 289 | 83 | 23,918 | Common | Form 4 ↗ |
| Andrew M. Dahl | SVP, Corporate Controller | 2026-05-07 | A | 3,020 | 0 | 0 | Common | Form 4 ↗ |
| Daniel J. Lippis | CVP, TAVR | 2026-05-07 | A | 7,850 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Wayne Markowitz | CVP, JAPAC | 2026-05-07 | D | 264 | 83 | 21,965 | Common | Form 4 ↗ |
| Wayne Markowitz | CVP, JAPAC | 2026-05-07 | D | 593 | 80 | 47,280 | Common | Form 4 ↗ |
| Bernard Zovighian | Director | 2026-05-07 | A | 43,800 | 0 | 0 | Common | Form 4 ↗ |
| Bernard Zovighian | Director | 2026-05-07 | D | 4,153 | 83 | 345,530 | Common | Form 4 ↗ |
| Bernard Zovighian | Director | 2026-05-07 | D | 5,489 | 0 | 0 | Common | Form 4 ↗ |
| Bernard Zovighian | Director | 2026-05-07 | A | 43,800 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Donald Bobo | CVP,Strategy/Corp Development | 2026-05-07 | A | 7,850 | 0 | 0 | Common | Form 4 ↗ |
| Scott Ullem | CVP, Chief Financial Officer | 2026-05-07 | D | 1,661 | 83 | 137,464 | Common | Form 4 ↗ |
| Daveen Chopra | CVP, TMTT & Surgical | 2026-05-07 | A | 9,675 | 0 | 0 | Common | Form 4 ↗ |
| Daniel J. Lippis | CVP, TAVR | 2026-05-07 | D | 309 | 83 | 25,709 | Common | Form 4 ↗ |
| Wayne Markowitz | CVP, JAPAC | 2026-05-07 | D | 226 | 83 | 18,704 | Common | Form 4 ↗ |
| Bernard Zovighian | Director | 2026-05-07 | A | 5,489 | 0 | 0 | Common | Form 4 ↗ |
| Wayne Markowitz | CVP, JAPAC | 2026-05-07 | A | 26,400 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Wayne Markowitz | CVP, JAPAC | 2026-05-07 | A | 5,200 | 0 | 0 | Common | Form 4 ↗ |
| Daniel J. Lippis | CVP, TAVR | 2026-05-07 | A | 7,850 | 0 | 0 | Common | Form 4 ↗ |
| Daniel J. Lippis | CVP, TAVR | 2026-05-07 | D | 450 | 83 | 37,242 | Common | Form 4 ↗ |
| Andrew M. Dahl | SVP, Corporate Controller | 2026-05-07 | A | 3,985 | 0 | 0 | Common | Form 4 ↗ |
| Andrew M. Dahl | SVP, Corporate Controller | 2026-05-07 | A | 6,745 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Donald Bobo | CVP,Strategy/Corp Development | 2026-05-07 | D | 831 | 83 | 69,139 | Common | Form 4 ↗ |
| Bernard Zovighian | Director | 2026-05-07 | D | 4,222 | 0 | 0 | Common | Form 4 ↗ |
| Bernard Zovighian | Director | 2026-05-07 | A | 245,300 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Nicholas J. Valeriani | Director | 2026-05-08 | A | 5,127 | 0 | 0 | Common | Form 4 ↗ |
| Kieran T. Gallahue | Director | 2026-05-08 | A | 3,251 | 0 | 0 | Common | Form 4 ↗ |
| Kieran T. Gallahue | Director | 2026-05-08 | A | 1,064 | 0 | 0 | Common | Form 4 ↗ |
| Heisz Leslie Stone | Director | 2026-05-08 | A | 3,251 | 0 | 0 | Common | Form 4 ↗ |
| Ramona Sequeira | Director | 2026-05-08 | A | 3,251 | 0 | 0 | Common | Form 4 ↗ |
| Steven R. Loranger | Director | 2026-05-08 | A | 1,064 | 0 | 0 | Common | Form 4 ↗ |
| Paul A. LaViolette | Director | 2026-05-08 | A | 3,251 | 0 | 0 | Common | Form 4 ↗ |
| David T. Feinberg | Director | 2026-05-08 | A | 3,251 | 0 | 0 | Common | Form 4 ↗ |
| Leslie C. Davis | Director | 2026-05-08 | A | 3,251 | 0 | 0 | Common | Form 4 ↗ |
| Steven R. Loranger | Director | 2026-05-08 | A | 3,251 | 0 | 0 | Common | Form 4 ↗ |
| Bernard Zovighian | Director | 2026-05-11 | A | 47,207 | 0 | 0 | Common | Form 4 ↗ |
| Scott Ullem | CVP, Chief Financial Officer | 2026-05-11 | D | 19,830 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Daniel J. Lippis | CVP, TAVR | 2026-05-11 | D | 362 | 80 | 28,946 | Common | Form 4 ↗ |
| Bernard Zovighian | Director | 2026-05-11 | A | 26,640 | 0 | 0 | Common | Form 4 ↗ |
| Scott Ullem | CVP, Chief Financial Officer | 2026-05-11 | D | 11,004 | 80 | 879,880 | Common | Form 4 ↗ |
| Daveen Chopra | CVP, TMTT & Surgical | 2026-05-11 | D | 7,538 | 80 | 602,738 | Common | Form 4 ↗ |
| Donald Bobo | CVP,Strategy/Corp Development | 2026-05-11 | D | 7,469 | 80 | 597,221 | Common | Form 4 ↗ |
| Donald Bobo | CVP,Strategy/Corp Development | 2026-05-11 | A | 13,457 | 0 | 0 | Common | Form 4 ↗ |
| Bernard Zovighian | Director | 2026-05-11 | D | 26,640 | 0 | 0 | Common | Form 4 ↗ |
| Bernard Zovighian | Director | 2026-05-11 | D | 26,198 | 80 | 2,094,792 | Common | Form 4 ↗ |
| Bernard Zovighian | Director | 2026-05-11 | D | 35,506 | 78 | 2,766,762 | Common, open-market sale | Form 4 ↗ |
| Bernard Zovighian | Director | 2026-05-11 | D | 47,207 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Daveen Chopra | CVP, TMTT & Surgical | 2026-05-11 | A | 13,583 | 0 | 0 | Common | Form 4 ↗ |
| Bernard Zovighian | Director | 2026-05-11 | D | 845 | 78 | 66,250 | Common, open-market sale | Form 4 ↗ |
| Donald Bobo | CVP,Strategy/Corp Development | 2026-05-11 | D | 13,457 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Daveen Chopra | CVP, TMTT & Surgical | 2026-05-11 | D | 13,583 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Scott Ullem | CVP, Chief Financial Officer | 2026-05-11 | A | 19,830 | 0 | 0 | Common | Form 4 ↗ |
| Donald Bobo | CVP,Strategy/Corp Development | 2026-05-15 | D | 8,000 | 82 | 654,573 | Common | Form 4 ↗ |
| Donald Bobo | CVP,Strategy/Corp Development | 2026-05-15 | D | 9,968 | 82 | 818,106 | Common, open-market sale | Form 4 ↗ |
| Daniel J. Lippis | CVP, TAVR | 2026-05-18 | D | 620 | 81 | 50,307 | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-05-18 | — | 620 | — | — | 1 insider, 1 accrual row | ||
| Daniel J. Lippis | CVP, TAVR | 2026-05-18 | A | 620 | 73 | 45,062 | Common | Form 4 ↗ |
| Daveen Chopra | CVP, TMTT & Surgical | 2026-05-22 | D | 1,500 | 85 | 126,905 | Common, open-market sale | Form 4 ↗ |
| Donald Bobo | CVP,Strategy/Corp Development | 2026-05-27 | D | 23,145 | 86 | 2,000,193 | Common, open-market sale | Form 4 ↗ |
| Andrew M. Dahl | SVP, Corporate Controller | 2026-05-29 | D | 567.53 | 86 | 48,853 | Common | Form 4 ↗ |
| Bernard Zovighian | Director | 2026-06-17 | D | 523 | 88 | 45,982 | Common | Form 4 ↗ |
| Daniel J. Lippis | CVP, TAVR | 2026-06-30 | A | 619 | 73 | 44,989 | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-06-30 | — | 619 | — | — | 1 insider, 1 accrual row | ||
| Daniel J. Lippis | CVP, TAVR | 2026-06-30 | D | 619 | 91 | 56,577 | Common, open-market sale | Form 4 ↗ |
| Daniel J. Lippis | CVP, TAVR | 2026-07-07 | D | 377 | 95 | 35,883 | Common | Form 4 ↗ |
| Theodora Mistras | CVP, Chief Financial Officer | 2026-07-09 | A | 12,325 | 0 | 0 | Common | Form 4 ↗ |
| Theodora Mistras | CVP, Chief Financial Officer | 2026-07-09 | A | 87,595 | 0 | 0 | Common | Form 4 ↗ |
| Theodora Mistras | CVP, Chief Financial Officer | 2026-07-09 | A | 61,800 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Theodora Mistras | CVP, Chief Financial Officer | 2026-07-09 | A | 12,325 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Daniel J. Lippis | CVP, TAVR | 2026-07-10 | A | 619 | 73 | 44,989 | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-07-10 | — | 619 | — | — | 1 insider, 1 accrual row | ||
| Daniel J. Lippis | CVP, TAVR | 2026-07-10 | D | 619 | 92 | 56,762 | Common | Form 4 ↗ |
| Annette Bruls | CVP, EMEACLA | 2026-07-11 | D | 109 | 92 | 10,051 | Common | Form 4 ↗ |
| Bernard Zovighian | Director | 2026-07-27 | D | 2,920.55 | 84 | 245,134 | Common | Form 4 ↗ |
| Bernard Zovighian | Director | 2026-07-27 | D | 319.65 | 0 | 0 | Common | Form 4 ↗ |
| Bernard Zovighian | Director | 2026-07-27 | A | 319.65 | 0 | 0 | Common | Form 4 ↗ |
| Wayne Markowitz | CVP, JAPAC | 2026-07-28 | A | 9,628 | 74 | 712,665 | Common | Form 4 ↗ |
| Wayne Markowitz | CVP, JAPAC | 2026-07-28 | D | 9,628 | 85 | 818,958 | Common | Form 4 ↗ |
| Wayne Markowitz | CVP, JAPAC | 2026-07-28 | D | 9,628 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Wayne Markowitz | CVP, JAPAC | 2026-07-30 | D | 146.31 | 86 | 12,588 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Donald Bobo | CVP,Strategy/Corp Development | 2026-04-02 | D | 22,680 | $0 | $0 | Derivative, Class A Common | Form 4 ↗ |
| Donald Bobo | CVP,Strategy/Corp Development | 2026-04-02 | A | 22,680 | 59 | 1,343,942 | Common | Form 4 ↗ |
| Donald Bobo | CVP,Strategy/Corp Development | 2026-04-02 | D | 4,676 | 81 | 376,846 | Common, open-market sale | Form 4 ↗ |
| Donald Bobo | CVP,Strategy/Corp Development | 2026-04-02 | D | 18,004 | 80 | 1,441,209 | Common, open-market sale | Form 4 ↗ |
| Daniel J. Lippis | CVP, TAVR | 2026-04-06 | D | 1,019 | 81 | 82,523 | Common, open-market sale | Form 4 ↗ |
| Daniel J. Lippis | CVP, TAVR | 2026-04-06 | A | 1,019 | 59 | 60,383 | Common | Form 4 ↗ |
| Daniel J. Lippis | CVP, TAVR | 2026-04-06 | D | 1,019 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Scott Ullem | CVP, Chief Financial Officer | 2026-04-09 | D | 4,676 | 80 | 376,401 | Common, open-market sale | Form 4 ↗ |
| Scott Ullem | CVP, Chief Financial Officer | 2026-04-09 | D | 13,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Scott Ullem | CVP, Chief Financial Officer | 2026-04-09 | A | 13,000 | 59 | 770,337 | Common | Form 4 ↗ |
| Scott Ullem | CVP, Chief Financial Officer | 2026-04-09 | D | 8,324 | 80 | 664,144 | Common, open-market sale | Form 4 ↗ |
| Daniel J. Lippis | CVP, TAVR | 2026-05-01 | D | 1,019 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Daniel J. Lippis | CVP, TAVR | 2026-05-01 | A | 1,019 | 59 | 60,383 | Common | Form 4 ↗ |
| Daniel J. Lippis | CVP, TAVR | 2026-05-01 | D | 19 | 84 | 1,596 | Common, open-market sale | Form 4 ↗ |
| Daniel J. Lippis | CVP, TAVR | 2026-05-01 | D | 1,019 | 84 | 85,576 | Common | Form 4 ↗ |
| Daniel J. Lippis | CVP, TAVR | 2026-05-01 | D | 252 | 84 | 21,163 | Common | Form 4 ↗ |
| Daniel J. Lippis | CVP, TAVR | 2026-05-01 | D | 1,019 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Daniel J. Lippis | CVP, TAVR | 2026-05-01 | D | 1,000 | 83 | 82,989 | Common, open-market sale | Form 4 ↗ |
| Daniel J. Lippis | CVP, TAVR | 2026-05-01 | A | 1,019 | 59 | 60,383 | Common | Form 4 ↗ |
| Donald Bobo | CVP,Strategy/Corp Development | 2026-05-03 | D | 469 | 84 | 39,387 | Common | Form 4 ↗ |
| Daveen Chopra | CVP, TMTT & Surgical | 2026-05-03 | D | 282 | 84 | 23,682 | Common | Form 4 ↗ |
| Scott Ullem | CVP, Chief Financial Officer | 2026-05-03 | A | 13,000 | 59 | 770,337 | Common | Form 4 ↗ |
| Bernard Zovighian | Director | 2026-05-03 | D | 523 | 0 | 0 | Common | Form 4 ↗ |
| Bernard Zovighian | Director | 2026-05-03 | A | 523 | 0 | 0 | Common | Form 4 ↗ |
| Scott Ullem | CVP, Chief Financial Officer | 2026-05-03 | D | 11,131 | 83 | 922,871 | Common | Form 4 ↗ |
| Scott Ullem | CVP, Chief Financial Officer | 2026-05-03 | D | 13,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Scott Ullem | CVP, Chief Financial Officer | 2026-05-03 | D | 620 | 84 | 52,068 | Common | Form 4 ↗ |
| Bernard Zovighian | Director | 2026-05-03 | D | 515 | 84 | 43,250 | Common | Form 4 ↗ |
| Daveen Chopra | CVP, TMTT & Surgical | 2026-05-07 | D | 674 | 83 | 56,077 | Common | Form 4 ↗ |
| Bernard Zovighian | Director | 2026-05-07 | D | 5,398 | 83 | 446,738 | Common | Form 4 ↗ |
| Wayne Markowitz | CVP, JAPAC | 2026-05-07 | A | 5,200 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Daniel J. Lippis | CVP, TAVR | 2026-05-07 | A | 39,900 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Daveen Chopra | CVP, TMTT & Surgical | 2026-05-07 | D | 1,141 | 83 | 94,429 | Common | Form 4 ↗ |
| Bernard Zovighian | Director | 2026-05-07 | A | 4,222 | 0 | 0 | Common | Form 4 ↗ |
| Donald Bobo | CVP,Strategy/Corp Development | 2026-05-07 | A | 7,850 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Scott Ullem | CVP, Chief Financial Officer | 2026-05-07 | D | 1,373 | 83 | 114,234 | Common | Form 4 ↗ |
| Donald Bobo | CVP,Strategy/Corp Development | 2026-05-07 | D | 1,038 | 83 | 85,905 | Common | Form 4 ↗ |
| Donald Bobo | CVP,Strategy/Corp Development | 2026-05-07 | A | 44,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Annette Bruls | CVP, EMEACLA | 2026-05-07 | A | 6,650 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Annette Bruls | CVP, EMEACLA | 2026-05-07 | A | 33,700 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Annette Bruls | CVP, EMEACLA | 2026-05-07 | D | 84 | 83 | 6,952 | Common | Form 4 ↗ |
| Annette Bruls | CVP, EMEACLA | 2026-05-07 | A | 6,650 | 0 | 0 | Common | Form 4 ↗ |
| Daveen Chopra | CVP, TMTT & Surgical | 2026-05-07 | A | 9,675 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Daveen Chopra | CVP, TMTT & Surgical | 2026-05-07 | A | 49,100 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Andrew M. Dahl | SVP, Corporate Controller | 2026-05-07 | D | 289 | 83 | 23,918 | Common | Form 4 ↗ |
| Andrew M. Dahl | SVP, Corporate Controller | 2026-05-07 | A | 3,020 | 0 | 0 | Common | Form 4 ↗ |
| Daniel J. Lippis | CVP, TAVR | 2026-05-07 | A | 7,850 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Wayne Markowitz | CVP, JAPAC | 2026-05-07 | D | 264 | 83 | 21,965 | Common | Form 4 ↗ |
| Wayne Markowitz | CVP, JAPAC | 2026-05-07 | D | 593 | 80 | 47,280 | Common | Form 4 ↗ |
| Bernard Zovighian | Director | 2026-05-07 | A | 43,800 | 0 | 0 | Common | Form 4 ↗ |
| Bernard Zovighian | Director | 2026-05-07 | D | 4,153 | 83 | 345,530 | Common | Form 4 ↗ |
| Bernard Zovighian | Director | 2026-05-07 | D | 5,489 | 0 | 0 | Common | Form 4 ↗ |
| Bernard Zovighian | Director | 2026-05-07 | A | 43,800 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Donald Bobo | CVP,Strategy/Corp Development | 2026-05-07 | A | 7,850 | 0 | 0 | Common | Form 4 ↗ |
| Scott Ullem | CVP, Chief Financial Officer | 2026-05-07 | D | 1,661 | 83 | 137,464 | Common | Form 4 ↗ |
| Daveen Chopra | CVP, TMTT & Surgical | 2026-05-07 | A | 9,675 | 0 | 0 | Common | Form 4 ↗ |
| Daniel J. Lippis | CVP, TAVR | 2026-05-07 | D | 309 | 83 | 25,709 | Common | Form 4 ↗ |
| Wayne Markowitz | CVP, JAPAC | 2026-05-07 | D | 226 | 83 | 18,704 | Common | Form 4 ↗ |
| Bernard Zovighian | Director | 2026-05-07 | A | 5,489 | 0 | 0 | Common | Form 4 ↗ |
| Wayne Markowitz | CVP, JAPAC | 2026-05-07 | A | 26,400 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Wayne Markowitz | CVP, JAPAC | 2026-05-07 | A | 5,200 | 0 | 0 | Common | Form 4 ↗ |
| Daniel J. Lippis | CVP, TAVR | 2026-05-07 | A | 7,850 | 0 | 0 | Common | Form 4 ↗ |
| Daniel J. Lippis | CVP, TAVR | 2026-05-07 | D | 450 | 83 | 37,242 | Common | Form 4 ↗ |
| Andrew M. Dahl | SVP, Corporate Controller | 2026-05-07 | A | 3,985 | 0 | 0 | Common | Form 4 ↗ |
| Andrew M. Dahl | SVP, Corporate Controller | 2026-05-07 | A | 6,745 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Donald Bobo | CVP,Strategy/Corp Development | 2026-05-07 | D | 831 | 83 | 69,139 | Common | Form 4 ↗ |
| Bernard Zovighian | Director | 2026-05-07 | D | 4,222 | 0 | 0 | Common | Form 4 ↗ |
| Bernard Zovighian | Director | 2026-05-07 | A | 245,300 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Nicholas J. Valeriani | Director | 2026-05-08 | A | 5,127 | 0 | 0 | Common | Form 4 ↗ |
| Kieran T. Gallahue | Director | 2026-05-08 | A | 3,251 | 0 | 0 | Common | Form 4 ↗ |
| Kieran T. Gallahue | Director | 2026-05-08 | A | 1,064 | 0 | 0 | Common | Form 4 ↗ |
| Heisz Leslie Stone | Director | 2026-05-08 | A | 3,251 | 0 | 0 | Common | Form 4 ↗ |
| Ramona Sequeira | Director | 2026-05-08 | A | 3,251 | 0 | 0 | Common | Form 4 ↗ |
| Steven R. Loranger | Director | 2026-05-08 | A | 1,064 | 0 | 0 | Common | Form 4 ↗ |
| Paul A. LaViolette | Director | 2026-05-08 | A | 3,251 | 0 | 0 | Common | Form 4 ↗ |
| David T. Feinberg | Director | 2026-05-08 | A | 3,251 | 0 | 0 | Common | Form 4 ↗ |
| Leslie C. Davis | Director | 2026-05-08 | A | 3,251 | 0 | 0 | Common | Form 4 ↗ |
| Steven R. Loranger | Director | 2026-05-08 | A | 3,251 | 0 | 0 | Common | Form 4 ↗ |
| Bernard Zovighian | Director | 2026-05-11 | A | 47,207 | 0 | 0 | Common | Form 4 ↗ |
| Scott Ullem | CVP, Chief Financial Officer | 2026-05-11 | D | 19,830 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Daniel J. Lippis | CVP, TAVR | 2026-05-11 | D | 362 | 80 | 28,946 | Common | Form 4 ↗ |
| Bernard Zovighian | Director | 2026-05-11 | A | 26,640 | 0 | 0 | Common | Form 4 ↗ |
| Scott Ullem | CVP, Chief Financial Officer | 2026-05-11 | D | 11,004 | 80 | 879,880 | Common | Form 4 ↗ |
| Daveen Chopra | CVP, TMTT & Surgical | 2026-05-11 | D | 7,538 | 80 | 602,738 | Common | Form 4 ↗ |
| Donald Bobo | CVP,Strategy/Corp Development | 2026-05-11 | D | 7,469 | 80 | 597,221 | Common | Form 4 ↗ |
| Donald Bobo | CVP,Strategy/Corp Development | 2026-05-11 | A | 13,457 | 0 | 0 | Common | Form 4 ↗ |
| Bernard Zovighian | Director | 2026-05-11 | D | 26,640 | 0 | 0 | Common | Form 4 ↗ |
| Bernard Zovighian | Director | 2026-05-11 | D | 26,198 | 80 | 2,094,792 | Common | Form 4 ↗ |
| Bernard Zovighian | Director | 2026-05-11 | D | 35,506 | 78 | 2,766,762 | Common, open-market sale | Form 4 ↗ |
| Bernard Zovighian | Director | 2026-05-11 | D | 47,207 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Daveen Chopra | CVP, TMTT & Surgical | 2026-05-11 | A | 13,583 | 0 | 0 | Common | Form 4 ↗ |
| Bernard Zovighian | Director | 2026-05-11 | D | 845 | 78 | 66,250 | Common, open-market sale | Form 4 ↗ |
| Donald Bobo | CVP,Strategy/Corp Development | 2026-05-11 | D | 13,457 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Daveen Chopra | CVP, TMTT & Surgical | 2026-05-11 | D | 13,583 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Scott Ullem | CVP, Chief Financial Officer | 2026-05-11 | A | 19,830 | 0 | 0 | Common | Form 4 ↗ |
| Donald Bobo | CVP,Strategy/Corp Development | 2026-05-15 | D | 8,000 | 82 | 654,573 | Common | Form 4 ↗ |
| Donald Bobo | CVP,Strategy/Corp Development | 2026-05-15 | D | 9,968 | 82 | 818,106 | Common, open-market sale | Form 4 ↗ |
| Daniel J. Lippis | CVP, TAVR | 2026-05-18 | D | 620 | 81 | 50,307 | Common | Form 4 ↗ |
| Daniel J. Lippis | CVP, TAVR | 2026-05-18 | D | 620 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Daniel J. Lippis | CVP, TAVR | 2026-05-18 | A | 620 | 73 | 45,062 | Common | Form 4 ↗ |
| Daveen Chopra | CVP, TMTT & Surgical | 2026-05-22 | D | 1,500 | 85 | 126,905 | Common, open-market sale | Form 4 ↗ |
| Donald Bobo | CVP,Strategy/Corp Development | 2026-05-27 | D | 23,145 | 86 | 2,000,193 | Common, open-market sale | Form 4 ↗ |
| Andrew M. Dahl | SVP, Corporate Controller | 2026-05-29 | D | 567.53 | 86 | 48,853 | Common | Form 4 ↗ |
| Bernard Zovighian | Director | 2026-06-17 | D | 523 | 88 | 45,982 | Common | Form 4 ↗ |
| Daniel J. Lippis | CVP, TAVR | 2026-06-30 | A | 619 | 73 | 44,989 | Common | Form 4 ↗ |
| Daniel J. Lippis | CVP, TAVR | 2026-06-30 | D | 619 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Daniel J. Lippis | CVP, TAVR | 2026-06-30 | D | 619 | 91 | 56,577 | Common, open-market sale | Form 4 ↗ |
| Daniel J. Lippis | CVP, TAVR | 2026-07-07 | D | 377 | 95 | 35,883 | Common | Form 4 ↗ |
| Theodora Mistras | CVP, Chief Financial Officer | 2026-07-09 | A | 12,325 | 0 | 0 | Common | Form 4 ↗ |
| Theodora Mistras | CVP, Chief Financial Officer | 2026-07-09 | A | 87,595 | 0 | 0 | Common | Form 4 ↗ |
| Theodora Mistras | CVP, Chief Financial Officer | 2026-07-09 | A | 61,800 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Theodora Mistras | CVP, Chief Financial Officer | 2026-07-09 | A | 12,325 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Daniel J. Lippis | CVP, TAVR | 2026-07-10 | A | 619 | 73 | 44,989 | Common | Form 4 ↗ |
| Daniel J. Lippis | CVP, TAVR | 2026-07-10 | D | 619 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Daniel J. Lippis | CVP, TAVR | 2026-07-10 | D | 619 | 92 | 56,762 | Common | Form 4 ↗ |
| Annette Bruls | CVP, EMEACLA | 2026-07-11 | D | 109 | 92 | 10,051 | Common | Form 4 ↗ |
| Bernard Zovighian | Director | 2026-07-27 | D | 2,920.55 | 84 | 245,134 | Common | Form 4 ↗ |
| Bernard Zovighian | Director | 2026-07-27 | D | 319.65 | 0 | 0 | Common | Form 4 ↗ |
| Bernard Zovighian | Director | 2026-07-27 | A | 319.65 | 0 | 0 | Common | Form 4 ↗ |
| Wayne Markowitz | CVP, JAPAC | 2026-07-28 | A | 9,628 | 74 | 712,665 | Common | Form 4 ↗ |
| Wayne Markowitz | CVP, JAPAC | 2026-07-28 | D | 9,628 | 85 | 818,958 | Common | Form 4 ↗ |
| Wayne Markowitz | CVP, JAPAC | 2026-07-28 | D | 9,628 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Wayne Markowitz | CVP, JAPAC | 2026-07-30 | D | 146.31 | 86 | 12,588 | Common | Form 4 ↗ |
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Bernard Zovighian | PSU | 2025-05-08 | — | 3,250,137 | — | — | $3,250,137 |
| Scott Ullem | OPTION | 2025-05-08 | 63 | — | 75,200 | — | 1,999,726 |
| Daveen Chopra | OPTION | 2025-05-08 | 63 | — | 47,000 | — | 1,375,784 |
| Larry Wood | PSU | 2025-05-08 | — | 824,662 | — | — | 824,662 |
| Larry Wood | OPTION | 2025-05-08 | 63 | — | 62,000 | — | 1,648,710 |
| Daveen Chopra | PSU | 2025-05-08 | — | 827,448 | — | — | 827,448 |
| Larry Wood | PSU | 2025-05-08 | — | 993,837 | — | — | 993,837 |
| Bernard Zovighian | PSU | 2025-05-08 | — | 3,916,887 | — | — | 3,916,887 |
| Bernard Zovighian | OPTION | 2025-05-08 | 63 | — | 244,400 | — | 6,499,109 |
| Scott Ullem | PSU | 2025-05-08 | — | 1,000,042 | — | — | 1,000,042 |
| Scott Ullem | PSU | 2025-05-08 | — | 1,205,196 | — | — | 1,205,196 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Bernard Zovighian | $0 | $7,167,024 | $6,499,109 | 52.4% |
| Scott Ullem | 0 | 2,205,238 | 1,999,726 | 52.4% |
| Daveen Chopra | 0 | 827,448 | 1,375,784 | 37.6% |
| Larry Wood | 0 | 1,818,499 | 1,648,710 | 52.4% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Scott Ullem | RSU | 1,250 | — | $106,563 |
| Donald Bobo | RSU | 944 | — | 80,476 |
| Donald Bobo | RSU | 35,400 | — | 3,017,850 |
| Scott Ullem | RSU | 971 | — | 82,778 |
| Daveen Chopra | RSU | 3,238 | — | 276,040 |
| Annette Brüls | Option | 31,600 | 74.63 | — |
| Bernard Zovighian | Option | 196,880 | 74.63 | — |
| Daveen Chopra | Option | 27,900 | 85.84 | — |
| Bernard Zovighian | Option | 133,800 | 85.84 | — |
| Scott Ullem | Option | 36,450 | 88.78 | — |
| Bernard Zovighian | PSU | 80,976 | — | 6,903,204 |
| Bernard Zovighian | RSU | 76,213 | — | 6,497,116 |
| Bernard Zovighian | RSU | 158,976 | — | 13,552,619 |
| Bernard Zovighian | RSU | 49,263 | — | 4,199,628 |
| Scott Ullem | RSU | 55,219 | — | 4,707,399 |
| Scott Ullem | PSU | 28,653 | — | 2,442,668 |
| Daveen Chopra | PSU | 21,706 | — | 1,850,437 |
| Daveen Chopra | RSU | 37,275 | — | 3,177,694 |
| Larry Wood | RSU | 19,338 | — | 1,648,522 |
| Donald Bobo | RSU | 14,656 | — | 1,249,445 |
| Donald Bobo | PSU | 17,557 | — | 1,496,734 |
| Daveen Chopra | RSU | 16,100 | — | 1,372,525 |
| Donald Bobo | RSU | 14,044 | — | 1,197,230 |
| Annette Brüls | PSU | 12,260 | — | 1,045,165 |
| Bernard Zovighian | RSU | 11,263 | — | 960,171 |
| Annette Brüls | RSU | 10,850 | — | 924,963 |
| Donald Bobo | RSU | 8,375 | — | 713,969 |
| Annette Brüls | RSU | 6,200 | — | 528,550 |
| Daveen Chopra | RSU | 7,000 | — | 596,750 |
| Donald Bobo | RSU | 6,700 | — | 571,175 |
| Scott Ullem | Option | 60,579 | 74.63 | — |
| Daveen Chopra | Option | 47,000 | 74.63 | — |
| Donald Bobo | RSU | 5,025 | — | 428,381 |
| Donald Bobo | Option | 37,862 | 74.63 | — |
| Donald Bobo | RSU | 3,213 | — | 273,908 |
| Daveen Chopra | RSU | 3,205 | — | 273,226 |
| Bernard Zovighian | RSU | 1,038 | — | 88,490 |
| Daveen Chopra | RSU | 813 | — | 69,308 |
| Bernard Zovighian | Option | 8,425 | 105.93 | — |
| Scott Ullem | Option | 10,150 | 105.93 | — |
| Donald Bobo | Option | 7,530 | 88.78 | — |
| Scott Ullem | Option | 30,932 | 85.84 | — |
| Annette Brüls | Option | 16,433 | 92.85 | — |
| Donald Bobo | Option | 18,701 | 85.84 | — |
| Daveen Chopra | Option | 24,950 | 88.78 | — |
| Daveen Chopra | Option | 6,600 | 105.93 | — |
| Bernard Zovighian | RSU | 43,550 | — | 3,712,638 |
| Bernard Zovighian | RSU | 33,500 | — | 2,855,875 |
| Bernard Zovighian | RSU | 25,125 | — | 2,141,906 |
| Scott Ullem | RSU | 23,450 | — | 1,999,113 |
| Scott Ullem | RSU | 20,694 | — | 1,764,142 |
| Larry Wood | RSU | 17,019 | — | 1,450,848 |
| Daveen Chopra | RSU | 14,175 | — | 1,208,419 |
| Scott Ullem | RSU | 13,400 | — | 1,142,350 |
| Scott Ullem | RSU | 11,075 | — | 944,144 |
| Daveen Chopra | RSU | 9,200 | — | 784,300 |
| Larry Wood | RSU | 8,725 | — | 743,806 |
| Scott Ullem | RSU | 8,307 | — | 708,172 |
| Annette Brüls | RSU | 6,060 | — | 516,615 |
| Annette Brüls | RSU | 5,477 | — | 466,914 |
| Daveen Chopra | RSU | 5,250 | — | 447,563 |
| Scott Ullem | RSU | 4,725 | — | 402,806 |
| Bernard Zovighian | Option | 86,850 | 88.78 | — |
Our executive compensation programs are designed to emphasize performance-based compensation, reward financial performance and the implementation of our corporate strategy, and to align the financial interests of our executives with those of our long-term stockholders.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Semler Brossy Consulting Group |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | True |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-05-07 | 424,961,639 | 50,924,101 | 0 | 89.3% | Passed |
| 2025 | 2025-05-08 | 412,893,480 | 56,265,224 | 0 | 88.01% | Passed |
| 2024 | 2024-05-07 | 433,346,235 | 42,323,309 | 0 | 91.1% | Passed |
| 2023 | 2023-05-11 | 438,121,670 | 43,074,168 | 0 | 91.05% | Passed |
| 2022 | 2022-05-03 | 450,501,744 | 49,851,515 | 1,494,852 | 89.77% | Passed |
| 2021 | 2021-05-04 | 465,845,853 | 35,298,524 | 1,387,564 | 92.7% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-05-07 | 89.3%a |
| 2025 | 2025-05-08 | 88.01%b |
| 2024 | 2024-05-07 | 91.1%c |
a. Approved under the standard stated in the filing — “Advisory Vote to Approve Named Executive Officer Compensation • Majority of shares represented at the Annual Meeting and entitled to vote on the proposal • Abstentions will have the effect of votes "against" • Broker non-votes will not be counted as shares entitled to vote on the proposal and therefore will have no effect on the outcome of the proposal Proposal 3.”.
b. Approved under the standard stated in the filing — “Advisory Vote to Approve Named Executive Officer Compensation • Majority of shares represented at the Annual Meeting and entitled to vote on the proposal • Abstentions will have the effect of votes "against" • Broker non-votes will not be counted as shares entitled to vote on the proposal Proposal 3.”.
c. Approved under the standard stated in the filing — “Advisory Vote to Approve Named Executive Officer Compensation • Majority of shares represented at the Annual Meeting and entitled to vote on the proposal • Abstentions will have the effect of votes "against" • Broker non-votes will not be counted as shares entitled to vote on the proposal Proposal 3.”.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | 194 : 1 |
|---|---|
| CEO total compensation | $17,454,255 |
| Median employee compensation | $89,827 |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Nicholas J. ValerianiIndependent · Board Chair · Compensation and Governance | $85,000 | $409,956 | $0 | $0 | $0 | $494,956 |
| Leslie S. HeiszIndependent · Audit (Chair) | 115,000 | 259,943 | 0 | 0 | 0 | 374,943 |
| Paul A. LaVioletteIndependent · Compensation and Governance (Chair) | 105,000 | 259,943 | 0 | 0 | 0 | 364,943 |
| Kieran T. GallahueIndependent · Audit | 90,027 | 259,943 | 0 | 0 | 0 | 349,970 |
| David T. FeinbergIndependent · Audit | 90,000 | 259,943 | 0 | 0 | 0 | 349,943 |
| Ramona SequeiraIndependent · Audit | 90,000 | 259,943 | 0 | 0 | 0 | 349,943 |
| Steven R. LorangerIndependent · Compensation and Governance | 85,027 | 259,943 | 0 | 0 | 0 | 344,970 |
| Leslie C. DavisIndependent · Compensation and Governance | 85,000 | 259,943 | 0 | 0 | 0 | 344,943 |
| Bernard ZovighianEmployee director | 0 | 0 | 0 | — | 0 | 0 |
| Annual cash retainer | — |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | $1,500 |
| Committee chair fees (audit / comp / nom-gov) | 25,000 / 20,000 / 20,000 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $745,054 |
| Equity awards (grant-date value) | $2,229,557 |
| All other compensation | $0 |
| Total cost of the board | $2,974,611 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies Edwards Lifesciences Corp names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Edwards Lifesciences Corp.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Baxter International Inc. | 2025 | Andrew Hider | $499,315 | $23,133,518 | $3,185,053 | $820,125 | $29,805,182 |
| 2 | Abbott Laboratories | 2025 | Robert Ford | 1,500,000 | 8,787,378 | 8,788,430 | 1,968,750 | 24,198,660 |
| 3 | Boston Scientific Corporation | 2025 | Michael Mahoney | 1,442,603 | 13,608,056 | 3,749,980 | 4,002,001 | 23,532,050 |
| 4 | Medtronic plc | 2026 | Geoffrey Martha | 1,399,039 | 13,672,200 | 5,175,559 | 2,307,200 | 22,940,252 |
| 5 | Stryker Corporation | 2025 | Kevin Lobo | 1,500,000 | 16,684,917 | 0 | 2,250,000 | 21,401,495 |
| 6 | Intuitive Surgical, Inc. | 2025 | David Rosa | 858,750 | 18,674,872 | 0 | 1,373,859 | 20,997,480 |
| 7 | Align Technology, Inc. | 2025 | Joseph Hogan | 1,400,000 | 16,556,872 | 0 | 1,220,100 | 19,193,988 |
| 8 | GE Healthcare Technologies Inc. | 2025 | Peter Arduini | 1,324,983 | 11,249,533 | 3,624,970 | 2,081,084 | 18,562,794 |
| 9 | Edwards Lifesciences Corp | 2025 | Bernard Zovighian | 1,192,500 | 7,167,024 | 6,499,109 | 2,406,537 | 17,454,255 |
| 10 | Becton, Dickinson and Company | 2025 | Thomas Polen | 1,395,463 | 9,991,854 | 3,311,861 | 1,852,010 | 17,129,140 |
| 11 | Zimmer Biomet Holdings, Inc. | 2025 | Ivan Tornos | 1,281,846 | 12,000,101 | 0 | 2,420,767 | 16,106,550 |
| 12 | The Cooper Companies, Inc. | 2025 | Albert White III | 1,170,769 | 6,642,918 | 6,643,050 | 1,525,951 | 16,051,141 |
| 13 | Hologic, Inc. | 2024 | Stephen MacMillan | 1,212,628 | 9,141,468 | 2,937,477 | 1,990,413 | 15,819,261 |
| 14 | ResMed Inc. | 2025 | Michael Farrell | 1,214,150 | 8,775,059 | 2,925,007 | 1,646,743 | 14,674,543 |
| 15 | IDEXX Laboratories, Inc. | 2025 | Jonathan Mazelsky | 1,150,000 | 5,399,881 | 5,400,001 | 2,593,000 | 14,580,122 |
| 16 | Agilent Technologies, Inc. | 2025 | Padraig McDonnell | 1,141,345 | 8,169,850 | 2,017,759 | 1,436,809 | 12,827,236 |
| 17 | Illumina, Inc. | 2025 | Jacob Thaysen | 1,000,000 | 8,763,122 | 0 | 1,155,000 | 11,018,895 |
| 18 | DexCom, Inc. | 2025 | Jacob Leach | 768,962 | 5,936,062 | 0 | 1,164,780 | 7,985,960 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Edwards Lifesciences Corp | 127% | Options 50 · PSU 25 · RSU 25 | No | Semler Brossy Consulting Group |
| Abbott Laboratories | 75.0% | Options 50 · PSU 50 | No | Meridian Compensation Partners, LLC |
| Agilent Technologies, Inc. | not disclosed | PSU 60 · Options 20 · RSU 20 | No | Semler Brossy |
| Align Technology, Inc. | 58.1% | MSU 70 · RSU 30 | Yes — Relative Total Stockholder Return (TSR) vs. Nasdaq Composite Index | Compensia, Inc. |
| Baxter International Inc. | not disclosed | PSU 50 · Stock Options 25 · RSU 25 | not disclosed | Aon |
| Becton, Dickinson and Company | 85% | PSU 50 · Options 25 · RSU 25 | No | Semler Brossy |
| Boston Scientific Corporation | 173% | PSU 50 · RSU 25 · Options 25 | No | Semler Brossy Consulting Group, LLC |
| DexCom, Inc. | not disclosed | not disclosed | Yes — Relative TSR Performance Metric | Aon Hewitt Consulting Company |
| GE Healthcare Technologies Inc. | 101% | PSU 50 · Options 25 · RSU 25 | No | Semler Brossy |
| Hologic, Inc. | 109% | PSU 50 · RSU 25 · Options 25 | No | not disclosed |
| IDEXX Laboratories, Inc. | 140% | Options 50 · PSU 50 | No | Farient |
| Illumina, Inc. | 1155% | not disclosed | Yes — 3-year rTSR performance against select companies in the Nasdaq Biotechnology Index | Aon (Aon's Human Capital Practice, a division of Aon, plc) |
| Intuitive Surgical, Inc. | 115.2% | RSU 50 · PSU 50 | No | Aon |
| Medtronic plc | 103% | PSU 50 · Options 30 · RSU 20 | No | Semler Brossy |
| ResMed Inc. | 102% | PSU 50 · RSU 25 · Options 25 | Yes — Absolute TSR | FW Cook, Inc. |
| Stryker Corporation | 100% | PSU 48 · Options 34 | No | Semler Brossy |
| The Cooper Companies, Inc. | 100.9% | Options 50 · PSU 50 | No | Compensia |
| Zimmer Biomet Holdings, Inc. | 125.9% | RSU 50 · PSU 50 | Yes — Relative TSR | Semler Brossy |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Bernard Zovighian | DEF 14A | 2026-03-26 | 0001099800-26-000015 | Section “Summary Compensation Table – Fiscal 2023-2025”. As printed: 17,454,255. Filing ↗machine: r2 · c27 · span 965441–965451 |
| 2 | Section 01, Scott Ullem | DEF 14A | 2026-03-26 | 0001099800-26-000015 | Section “Summary Compensation Table – Fiscal 2023-2025”. As printed: 6,050,554. Filing ↗machine: r5 · c27 · span 972045–972054 |
| 3 | Section 01, Larry Wood | DEF 14A | 2026-03-26 | 0001099800-26-000015 | Section “Summary Compensation Table – Fiscal 2023-2025”. As printed: 4,854,339. Filing ↗machine: r15 · c27 · span 992711–992720 |
| 4 | Section 01, Daveen Chopra | DEF 14A | 2026-03-26 | 0001099800-26-000015 | Section “Summary Compensation Table – Fiscal 2023-2025”. As printed: 4,695,742. Filing ↗machine: r13 · c27 · span 988051–988060 |
| 5 | Section 01, Donald Bobo | DEF 14A | 2026-03-26 | 0001099800-26-000015 | Section “Summary Compensation Table – Fiscal 2023-2025”. As printed: 4,223,365. Filing ↗machine: r8 · c27 · span 978450–978459 |
| 6 | Section 01, Annette Brüls | DEF 14A | 2026-03-26 | 0001099800-26-000015 | Section “Summary Compensation Table – Fiscal 2023-2025”. As printed: 3,732,107. Filing ↗machine: r11 · c27 · span 985105–985114 |
| 7 | Section 03, Bernard Zovighian PSU | DEF 14A | 2026-03-26 | 0001099800-26-000015 | Section “Grants of Plan-Based Awards in Fiscal Year 2025” · grants of plan-based awards table. Filing ↗machine: t59 · r4 · c2 · span 911028–911037 |
| 8 | Section 03, Scott Ullem OPTION | DEF 14A | 2026-03-26 | 0001099800-26-000015 | Section “Grants of Plan-Based Awards in Fiscal Year 2025” · grants of plan-based awards table. Filing ↗machine: t62 · r5 · c5 · span 971224–971233 |
| 9 | Section 03, Daveen Chopra OPTION | DEF 14A | 2026-03-26 | 0001099800-26-000015 | Section “Grants of Plan-Based Awards in Fiscal Year 2025” · grants of plan-based awards table. Filing ↗machine: t96 · r1 · c1 · span 1837081–1837087 |
| 10 | Section 03, Larry Wood PSU | DEF 14A | 2026-03-26 | 0001099800-26-000015 | Section “Grants of Plan-Based Awards in Fiscal Year 2025” · grants of plan-based awards table. Filing ↗machine: t59 · r9 · c2 · span 916096–916103 |
| 11 | Section 03, Larry Wood OPTION | DEF 14A | 2026-03-26 | 0001099800-26-000015 | Section “Grants of Plan-Based Awards in Fiscal Year 2025” · grants of plan-based awards table. Filing ↗machine: t96 · r3 · c1 · span 1838207–1838213 |
| 12 | Section 03, Daveen Chopra PSU | DEF 14A | 2026-03-26 | 0001099800-26-000015 | Section “Grants of Plan-Based Awards in Fiscal Year 2025” · grants of plan-based awards table. Filing ↗machine: t59 · r8 · c5 · span 915465–915472 |
| 13 | Section 03, Larry Wood PSU | DEF 14A | 2026-03-26 | 0001099800-26-000015 | Section “Grants of Plan-Based Awards in Fiscal Year 2025” · grants of plan-based awards table. Filing ↗machine: t59 · r9 · c5 · span 916476–916483 |
| 14 | Section 03, Bernard Zovighian PSU | DEF 14A | 2026-03-26 | 0001099800-26-000015 | Section “Grants of Plan-Based Awards in Fiscal Year 2025” · grants of plan-based awards table. Filing ↗machine: t59 · r4 · c5 · span 911389–911398 |
| 15 | Section 03, Bernard Zovighian OPTION | DEF 14A | 2026-03-26 | 0001099800-26-000015 | Section “Grants of Plan-Based Awards in Fiscal Year 2025” · grants of plan-based awards table. Filing ↗machine: t95 · r2 · c1 · span 1830943–1830950 |
| 16 | Section 03, Scott Ullem PSU | DEF 14A | 2026-03-26 | 0001099800-26-000015 | Section “Grants of Plan-Based Awards in Fiscal Year 2025” · grants of plan-based awards table. Filing ↗machine: t59 · r5 · c2 · span 912096–912105 |
| 17 | Section 03, Scott Ullem PSU | DEF 14A | 2026-03-26 | 0001099800-26-000015 | Section “Grants of Plan-Based Awards in Fiscal Year 2025” · grants of plan-based awards table. Filing ↗machine: t59 · r5 · c5 · span 912382–912391 |
| 18 | Section 07, pay ratio | DEF 14A | 2026-03-26 | 0001099800-26-000015 | Section “CEO Pay Ratio”. As printed: 194 : 1. Filing ↗ |
| 19 | Section 08, Nicholas J. Valeriani | DEF 14A | 2026-03-26 | 0001099800-26-000015 | Section “Director Compensation”. As printed: 494,956. Filing ↗machine: t42 · r9 · c4 · span 623292–623299 |
| 20 | Section 08, Leslie S. Heisz | DEF 14A | 2026-03-26 | 0001099800-26-000015 | Section “Director Compensation”. As printed: 374,943. Filing ↗machine: t42 · r5 · c4 · span 618638–618645 |
| 21 | Section 08, Paul A. LaViolette | DEF 14A | 2026-03-26 | 0001099800-26-000015 | Section “Director Compensation”. As printed: 364,943. Filing ↗machine: t42 · r6 · c4 · span 619799–619806 |
| 22 | Section 08, Kieran T. Gallahue | DEF 14A | 2026-03-26 | 0001099800-26-000015 | Section “Director Compensation”. As printed: 349,970. Filing ↗machine: t42 · r4 · c4 · span 617477–617484 |
| 23 | Section 08, David T. Feinberg | DEF 14A | 2026-03-26 | 0001099800-26-000015 | Section “Director Compensation”. As printed: 349,943. Filing ↗machine: t42 · r3 · c4 · span 616317–616324 |
| 24 | Section 08, Ramona Sequeira | DEF 14A | 2026-03-26 | 0001099800-26-000015 | Section “Director Compensation”. As printed: 349,943. Filing ↗machine: t42 · r8 · c4 · span 622128–622135 |
| 25 | Section 08, Steven R. Loranger | DEF 14A | 2026-03-26 | 0001099800-26-000015 | Section “Director Compensation”. As printed: 344,970. Filing ↗machine: t42 · r7 · c4 · span 620965–620972 |
| 26 | Section 08, Leslie C. Davis | DEF 14A | 2026-03-26 | 0001099800-26-000015 | Section “Director Compensation”. As printed: 344,943. Filing ↗machine: t42 · r2 · c4 · span 615324–615338 |
| 27 | Section 08, Bernard Zovighian | DEF 14A | 2026-03-26 | 0001099800-26-000015 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 28 | Section 02, Donald Bobo 2026-04-02 | Form 4 | 2026-04-02 | 0001225208-26-004249 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 29 | Section 02, Donald Bobo 2026-04-02 | Form 4 | 2026-04-02 | 0001225208-26-004249 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 30 | Section 02, Donald Bobo 2026-04-02 | Form 4 | 2026-04-02 | 0001225208-26-004249 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 31 | Section 02, Donald Bobo 2026-04-02 | Form 4 | 2026-04-02 | 0001225208-26-004249 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 32 | Section 02, Daniel J. Lippis 2026-04-06 | Form 4 | 2026-04-06 | 0001225208-26-004422 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 33 | Section 02, Daniel J. Lippis 2026-04-06 | Form 4 | 2026-04-06 | 0001225208-26-004422 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 34 | Section 02, Daniel J. Lippis 2026-04-06 | Form 4 | 2026-04-06 | 0001225208-26-004422 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 35 | Section 02, Scott Ullem 2026-04-09 | Form 4 | 2026-04-09 | 0001225208-26-004476 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 36 | Section 02, Scott Ullem 2026-04-09 | Form 4 | 2026-04-09 | 0001225208-26-004476 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 37 | Section 02, Scott Ullem 2026-04-09 | Form 4 | 2026-04-09 | 0001225208-26-004476 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 38 | Section 02, Scott Ullem 2026-04-09 | Form 4 | 2026-04-09 | 0001225208-26-004476 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 39 | Section 02, Daniel J. Lippis 2026-05-01 | Form 4 | 2026-05-04 | 0001225208-26-004909 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 40 | Section 02, Daniel J. Lippis 2026-05-01 | Form 4 | 2026-05-04 | 0001225208-26-004909 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 41 | Section 02, Daniel J. Lippis 2026-05-01 | Form 4 | 2026-05-04 | 0001225208-26-004909 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 42 | Section 02, Daniel J. Lippis 2026-05-01 | Form 4 | 2026-05-04 | 0001225208-26-004909 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 43 | Section 02, Daniel J. Lippis 2026-05-01 | Form 4 | 2026-05-04 | 0001225208-26-004909 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 44 | Section 02, Daniel J. Lippis 2026-05-01 | Form 4 | 2026-05-04 | 0001225208-26-004909 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 45 | Section 02, Daniel J. Lippis 2026-05-01 | Form 4 | 2026-05-04 | 0001225208-26-004909 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 46 | Section 02, Daniel J. Lippis 2026-05-01 | Form 4 | 2026-05-04 | 0001225208-26-004909 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 47 | Section 02, Donald Bobo 2026-05-03 | Form 4 | 2026-05-04 | 0001225208-26-004907 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 48 | Section 02, Daveen Chopra 2026-05-03 | Form 4 | 2026-05-04 | 0001225208-26-004908 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 49 | Section 02, Scott Ullem 2026-05-03 | Form 4 | 2026-05-05 | 0001225208-26-004969 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 50 | Section 02, Bernard Zovighian 2026-05-03 | Form 4 | 2026-05-05 | 0001225208-26-004968 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 51 | Section 02, Bernard Zovighian 2026-05-03 | Form 4 | 2026-05-05 | 0001225208-26-004968 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 52 | Section 02, Scott Ullem 2026-05-03 | Form 4 | 2026-05-05 | 0001225208-26-004969 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 53 | Section 02, Scott Ullem 2026-05-03 | Form 4 | 2026-05-05 | 0001225208-26-004969 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 54 | Section 02, Scott Ullem 2026-05-03 | Form 4 | 2026-05-05 | 0001225208-26-004969 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 55 | Section 02, Bernard Zovighian 2026-05-03 | Form 4 | 2026-05-05 | 0001225208-26-004968 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 56 | Section 02, Daveen Chopra 2026-05-07 | Form 4 | 2026-05-08 | 0001225208-26-005043 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 57 | Section 02, Bernard Zovighian 2026-05-07 | Form 4 | 2026-05-11 | 0001225208-26-005131 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 58 | Section 02, Wayne Markowitz 2026-05-07 | Form 4 | 2026-05-11 | 0001225208-26-005132 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 59 | Section 02, Daniel J. Lippis 2026-05-07 | Form 4 | 2026-05-08 | 0001225208-26-005045 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 60 | Section 02, Daveen Chopra 2026-05-07 | Form 4 | 2026-05-08 | 0001225208-26-005043 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 61 | Section 02, Bernard Zovighian 2026-05-07 | Form 4 | 2026-05-11 | 0001225208-26-005131 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 62 | Section 02, Donald Bobo 2026-05-07 | Form 4 | 2026-05-08 | 0001225208-26-005048 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 63 | Section 02, Scott Ullem 2026-05-07 | Form 4 | 2026-05-08 | 0001225208-26-005047 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 64 | Section 02, Donald Bobo 2026-05-07 | Form 4 | 2026-05-08 | 0001225208-26-005048 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 65 | Section 02, Donald Bobo 2026-05-07 | Form 4 | 2026-05-08 | 0001225208-26-005048 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 66 | Section 02, Annette Bruls 2026-05-07 | Form 4 | 2026-05-08 | 0001225208-26-005042 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 67 | Section 02, Annette Bruls 2026-05-07 | Form 4 | 2026-05-08 | 0001225208-26-005042 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 68 | Section 02, Annette Bruls 2026-05-07 | Form 4 | 2026-05-08 | 0001225208-26-005042 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 69 | Section 02, Annette Bruls 2026-05-07 | Form 4 | 2026-05-08 | 0001225208-26-005042 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 70 | Section 02, Daveen Chopra 2026-05-07 | Form 4 | 2026-05-08 | 0001225208-26-005043 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 71 | Section 02, Daveen Chopra 2026-05-07 | Form 4 | 2026-05-08 | 0001225208-26-005043 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 72 | Section 02, Andrew M. Dahl 2026-05-07 | Form 4 | 2026-05-08 | 0001225208-26-005044 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 73 | Section 02, Andrew M. Dahl 2026-05-07 | Form 4 | 2026-05-08 | 0001225208-26-005044 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 74 | Section 02, Daniel J. Lippis 2026-05-07 | Form 4 | 2026-05-08 | 0001225208-26-005045 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 75 | Section 02, Wayne Markowitz 2026-05-07 | Form 4 | 2026-05-11 | 0001225208-26-005132 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 76 | Section 02, Wayne Markowitz 2026-05-07 | Form 4 | 2026-05-11 | 0001225208-26-005132 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 77 | Section 02, Bernard Zovighian 2026-05-07 | Form 4 | 2026-05-11 | 0001225208-26-005131 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 78 | Section 02, Bernard Zovighian 2026-05-07 | Form 4 | 2026-05-11 | 0001225208-26-005131 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 79 | Section 02, Bernard Zovighian 2026-05-07 | Form 4 | 2026-05-11 | 0001225208-26-005131 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 80 | Section 02, Bernard Zovighian 2026-05-07 | Form 4 | 2026-05-11 | 0001225208-26-005131 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 81 | Section 02, Donald Bobo 2026-05-07 | Form 4 | 2026-05-08 | 0001225208-26-005048 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 82 | Section 02, Scott Ullem 2026-05-07 | Form 4 | 2026-05-08 | 0001225208-26-005047 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 83 | Section 02, Daveen Chopra 2026-05-07 | Form 4 | 2026-05-08 | 0001225208-26-005043 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 84 | Section 02, Daniel J. Lippis 2026-05-07 | Form 4 | 2026-05-08 | 0001225208-26-005045 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 85 | Section 02, Wayne Markowitz 2026-05-07 | Form 4 | 2026-05-11 | 0001225208-26-005132 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 86 | Section 02, Bernard Zovighian 2026-05-07 | Form 4 | 2026-05-11 | 0001225208-26-005131 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 87 | Section 02, Wayne Markowitz 2026-05-07 | Form 4 | 2026-05-11 | 0001225208-26-005132 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 88 | Section 02, Wayne Markowitz 2026-05-07 | Form 4 | 2026-05-11 | 0001225208-26-005132 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 89 | Section 02, Daniel J. Lippis 2026-05-07 | Form 4 | 2026-05-08 | 0001225208-26-005045 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 90 | Section 02, Daniel J. Lippis 2026-05-07 | Form 4 | 2026-05-08 | 0001225208-26-005045 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 91 | Section 02, Andrew M. Dahl 2026-05-07 | Form 4 | 2026-05-08 | 0001225208-26-005044 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 92 | Section 02, Andrew M. Dahl 2026-05-07 | Form 4 | 2026-05-08 | 0001225208-26-005044 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 93 | Section 02, Donald Bobo 2026-05-07 | Form 4 | 2026-05-08 | 0001225208-26-005048 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 94 | Section 02, Bernard Zovighian 2026-05-07 | Form 4 | 2026-05-11 | 0001225208-26-005131 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 95 | Section 02, Bernard Zovighian 2026-05-07 | Form 4 | 2026-05-11 | 0001225208-26-005131 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 96 | Section 02, Nicholas J. Valeriani 2026-05-08 | Form 4 | 2026-05-08 | 0001225208-26-005055 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 97 | Section 02, Kieran T. Gallahue 2026-05-08 | Form 4 | 2026-05-08 | 0001225208-26-005050 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 98 | Section 02, Kieran T. Gallahue 2026-05-08 | Form 4 | 2026-05-08 | 0001225208-26-005050 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 99 | Section 02, Heisz Leslie Stone 2026-05-08 | Form 4 | 2026-05-08 | 0001225208-26-005051 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 100 | Section 02, Ramona Sequeira 2026-05-08 | Form 4 | 2026-05-08 | 0001225208-26-005054 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 101 | Section 02, Steven R. Loranger 2026-05-08 | Form 4 | 2026-05-08 | 0001225208-26-005053 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 102 | Section 02, Paul A. LaViolette 2026-05-08 | Form 4 | 2026-05-08 | 0001225208-26-005052 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 103 | Section 02, David T. Feinberg 2026-05-08 | Form 4 | 2026-05-08 | 0001225208-26-005049 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 104 | Section 02, Leslie C. Davis 2026-05-08 | Form 4 | 2026-05-08 | 0001225208-26-005046 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 105 | Section 02, Steven R. Loranger 2026-05-08 | Form 4 | 2026-05-08 | 0001225208-26-005053 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 106 | Section 02, Bernard Zovighian 2026-05-11 | Form 4 | 2026-05-12 | 0001225208-26-005172 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 107 | Section 02, Scott Ullem 2026-05-11 | Form 4 | 2026-05-11 | 0001225208-26-005133 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 108 | Section 02, Daniel J. Lippis 2026-05-11 | Form 4 | 2026-05-11 | 0001225208-26-005130 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 109 | Section 02, Bernard Zovighian 2026-05-11 | Form 4 | 2026-05-12 | 0001225208-26-005172 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 110 | Section 02, Scott Ullem 2026-05-11 | Form 4 | 2026-05-11 | 0001225208-26-005133 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 111 | Section 02, Daveen Chopra 2026-05-11 | Form 4 | 2026-05-12 | 0001225208-26-005170 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 112 | Section 02, Donald Bobo 2026-05-11 | Form 4 | 2026-05-12 | 0001225208-26-005171 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 113 | Section 02, Donald Bobo 2026-05-11 | Form 4 | 2026-05-12 | 0001225208-26-005171 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 114 | Section 02, Bernard Zovighian 2026-05-11 | Form 4 | 2026-05-12 | 0001225208-26-005172 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 115 | Section 02, Bernard Zovighian 2026-05-11 | Form 4 | 2026-05-12 | 0001225208-26-005172 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 116 | Section 02, Bernard Zovighian 2026-05-11 | Form 4 | 2026-05-12 | 0001225208-26-005172 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 117 | Section 02, Bernard Zovighian 2026-05-11 | Form 4 | 2026-05-12 | 0001225208-26-005172 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 118 | Section 02, Daveen Chopra 2026-05-11 | Form 4 | 2026-05-12 | 0001225208-26-005170 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 119 | Section 02, Bernard Zovighian 2026-05-11 | Form 4 | 2026-05-12 | 0001225208-26-005172 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 120 | Section 02, Donald Bobo 2026-05-11 | Form 4 | 2026-05-12 | 0001225208-26-005171 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 121 | Section 02, Daveen Chopra 2026-05-11 | Form 4 | 2026-05-12 | 0001225208-26-005170 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 122 | Section 02, Scott Ullem 2026-05-11 | Form 4 | 2026-05-11 | 0001225208-26-005133 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 123 | Section 02, Donald Bobo 2026-05-15 | Form 4 | 2026-05-18 | 0001225208-26-005463 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 124 | Section 02, Donald Bobo 2026-05-15 | Form 4 | 2026-05-18 | 0001225208-26-005463 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 125 | Section 02, Daniel J. Lippis 2026-05-18 | Form 4 | 2026-05-18 | 0001225208-26-005464 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 126 | Section 02, Daniel J. Lippis 2026-05-18 | Form 4 | 2026-05-18 | 0001225208-26-005464 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 127 | Section 02, Daniel J. Lippis 2026-05-18 | Form 4 | 2026-05-18 | 0001225208-26-005464 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 128 | Section 02, Daveen Chopra 2026-05-22 | Form 4 | 2026-05-22 | 0001225208-26-005576 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 129 | Section 02, Donald Bobo 2026-05-27 | Form 4 | 2026-05-27 | 0001225208-26-005610 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 130 | Section 02, Andrew M. Dahl 2026-05-29 | Form 4 | 2026-05-29 | 0001225208-26-005647 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 131 | Section 02, Bernard Zovighian 2026-06-17 | Form 4 | 2026-06-17 | 0001225208-26-006103 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 132 | Section 02, Daniel J. Lippis 2026-06-30 | Form 4 | 2026-06-30 | 0001225208-26-006263 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 133 | Section 02, Daniel J. Lippis 2026-06-30 | Form 4 | 2026-06-30 | 0001225208-26-006263 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 134 | Section 02, Daniel J. Lippis 2026-06-30 | Form 4 | 2026-06-30 | 0001225208-26-006263 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 135 | Section 02, Daniel J. Lippis 2026-07-07 | Form 4 | 2026-07-07 | 0001225208-26-006535 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 136 | Section 02, Theodora Mistras 2026-07-09 | Form 4 | 2026-07-10 | 0001225208-26-006578 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 137 | Section 02, Theodora Mistras 2026-07-09 | Form 4 | 2026-07-10 | 0001225208-26-006578 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 138 | Section 02, Theodora Mistras 2026-07-09 | Form 4 | 2026-07-10 | 0001225208-26-006578 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 139 | Section 02, Theodora Mistras 2026-07-09 | Form 4 | 2026-07-10 | 0001225208-26-006578 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 140 | Section 02, Daniel J. Lippis 2026-07-10 | Form 4 | 2026-07-10 | 0001225208-26-006576 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 141 | Section 02, Daniel J. Lippis 2026-07-10 | Form 4 | 2026-07-10 | 0001225208-26-006576 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 142 | Section 02, Daniel J. Lippis 2026-07-10 | Form 4 | 2026-07-10 | 0001225208-26-006576 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 143 | Section 02, Annette Bruls 2026-07-11 | Form 4 | 2026-07-13 | 0001225208-26-006591 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 144 | Section 02, Bernard Zovighian 2026-07-27 | Form 4 | 2026-07-27 | 0001225208-26-006743 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 145 | Section 02, Bernard Zovighian 2026-07-27 | Form 4 | 2026-07-27 | 0001225208-26-006743 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 146 | Section 02, Bernard Zovighian 2026-07-27 | Form 4 | 2026-07-27 | 0001225208-26-006743 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 147 | Section 02, Wayne Markowitz 2026-07-28 | Form 4 | 2026-07-28 | 0001225208-26-006777 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 148 | Section 02, Wayne Markowitz 2026-07-28 | Form 4 | 2026-07-28 | 0001225208-26-006777 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 149 | Section 02, Wayne Markowitz 2026-07-28 | Form 4 | 2026-07-28 | 0001225208-26-006777 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 150 | Section 02, Wayne Markowitz 2026-07-30 | Form 4 | 2026-07-30 | 0001225208-26-006853 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 151 | Section 06, 2026 vote | Form 8-K | 2026-05-08 | 0001099800-26-000028 | Item 5.07 · say-on-pay result. As reported: 89.3% (votes for as printed: 424,961,639). Filing ↗ |
| 152 | Section 06, 2025 vote | Form 8-K | 2025-05-08 | 0001099800-25-000026 | Item 5.07 · say-on-pay result. As reported: 88.01% (votes for as printed: 412,893,480.47). Filing ↗ |
| 153 | Section 06, 2024 vote | Form 8-K | 2024-05-08 | 0001099800-24-000045 | Item 5.07 · say-on-pay result. As reported: 91.1% (votes for as printed: 433,346,235.39). Filing ↗ |
| 154 | Section 01 trend, Δ column (computed) | Computed | — | computed | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 155 | Section 03b vehicle mix (computed) | Computed | — | computed | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 156 | Section 09b board cost (computed) | Computed | — | computed | Cash 745,054 + equity 2,229,557 + all other 0 = 2,974,611, summed across the director compensation table rows.machine: formula: Σ = 2,974,611 |
| 157 | Baxter International Inc., Section 10b CEO total | DEF 14A | 2026-03-23 | 0001628280-26-020330 | CEO total compensation as printed in Baxter International Inc.'s own proxy. As printed: 29,805,182. Filing ↗machine: r4 · c30 · span 1451066–1451076 |
| 158 | Abbott Laboratories, Section 10b CEO total | DEF 14A | 2026-03-13 | 0001308179-26-000064 | CEO total compensation as printed in Abbott Laboratories's own proxy. As printed: 24,198,660. Filing ↗machine: span 1245488–1245498 |
| 159 | Boston Scientific Corporation, Section 10b CEO total | DEF 14A | 2026-03-18 | 0000885725-26-000025 | CEO total compensation as printed in Boston Scientific Corporation's own proxy. As printed: 23,532,050. Filing ↗machine: r2 · c27 · span 1249807–1249817 |
| 160 | Medtronic plc, Section 10b CEO total | DEF 14A | 2026-08-17 | 0001613103-26-000010 | CEO total compensation as printed in Medtronic plc's own proxy. As printed: 22,940,252. Filing ↗machine: span 988220–988230 |
| 161 | Stryker Corporation, Section 10b CEO total | DEF 14A | 2026-03-23 | 0000310764-26-000013 | CEO total compensation as printed in Stryker Corporation's own proxy. As printed: 21,401,495. Filing ↗machine: t101 · r2 · c7 · span 1584979–1584989 |
| 162 | Intuitive Surgical, Inc., Section 10b CEO total | DEF 14A | 2026-03-13 | 0001035267-26-000023 | CEO total compensation as printed in Intuitive Surgical, Inc.'s own proxy. As printed: 20,997,480. Filing ↗machine: r2 · c48 · span 762289–762299 |
| 163 | Align Technology, Inc., Section 10b CEO total | DEF 14A | 2026-04-07 | 0001097149-26-000023 | CEO total compensation as printed in Align Technology, Inc.'s own proxy. As printed: 19,193,988. Filing ↗machine: r2 · c42 · span 933168–933178 |
| 164 | GE Healthcare Technologies Inc., Section 10b CEO total | DEF 14A | 2026-03-19 | 0001932393-26-000021 | CEO total compensation as printed in GE Healthcare Technologies Inc.'s own proxy. As printed: 18,562,794. Filing ↗machine: t113 · r3 · c20 · span 924977–924987 |
| 165 | Edwards Lifesciences Corp (subject), Section 10b CEO total | DEF 14A | 2026-03-26 | 0001099800-26-000015 | CEO total compensation as printed in Edwards Lifesciences Corp's own proxy. As printed: 17,454,255. Filing ↗machine: r2 · c27 · span 965441–965451 |
| 166 | Becton, Dickinson and Company, Section 10b CEO total | DEF 14A | 2025-12-18 | 0001628280-25-057846 | CEO total compensation as printed in Becton, Dickinson and Company's own proxy. As printed: 17,129,140. Filing ↗machine: r2 · c27 · span 1173285–1173295 |
| 167 | Zimmer Biomet Holdings, Inc., Section 10b CEO total | DEF 14A | 2026-04-01 | 0001193125-26-135661 | CEO total compensation as printed in Zimmer Biomet Holdings, Inc.'s own proxy. As printed: 16,106,550. Filing ↗machine: t111 · r3 · c16 · span 1895785–1895795 |
| 168 | The Cooper Companies, Inc., Section 10b CEO total | DEF 14A | 2026-02-24 | 0001628280-26-011110 | CEO total compensation as printed in The Cooper Companies, Inc.'s own proxy. As printed: 16,051,141. Filing ↗machine: t120 · r3 · c14 · span 744904–744914 |
| 169 | Hologic, Inc., Section 10b CEO total | DEF 14A | 2025-01-16 | 0001140361-25-001287 | CEO total compensation as printed in Hologic, Inc.'s own proxy. As printed: 15,819,261. Filing ↗machine: r2 · c25 · span 1549664–1549674 |
| 170 | ResMed Inc., Section 10b CEO total | DEF 14A | 2025-10-02 | 0000943819-25-000079 | CEO total compensation as printed in ResMed Inc.'s own proxy. As printed: 14,674,543. Filing ↗machine: span 1328668–1328678 |
| 171 | IDEXX Laboratories, Inc., Section 10b CEO total | DEF 14A | 2026-03-27 | 0000874716-26-000064 | CEO total compensation as printed in IDEXX Laboratories, Inc.'s own proxy. As printed: 14,580,122. Filing ↗machine: span 1576008–1576018 |
| 172 | Agilent Technologies, Inc., Section 10b CEO total | DEF 14A | 2026-02-06 | 0001193125-26-040286 | CEO total compensation as printed in Agilent Technologies, Inc.'s own proxy. As printed: 12,827,236. Filing ↗machine: r3 · c29 · span 1450982–1450992 |
| 173 | Illumina, Inc., Section 10b CEO total | DEF 14A | 2026-04-09 | 0001193125-26-149669 | CEO total compensation as printed in Illumina, Inc.'s own proxy. As printed: 11,018,895. Filing ↗machine: r4 · c14 · span 728526–728536 |
| 174 | DexCom, Inc., Section 10b CEO total | DEF 14A | 2026-04-15 | 0001093557-26-000061 | CEO total compensation as printed in DexCom, Inc.'s own proxy. As printed: 7,985,960. Filing ↗machine: span 940364–940373 |
| 175 | Section 10a, Align Technology, Inc. reciprocity | DEF 14A | — | 0001097149-26-000023 | Align Technology, Inc. names Edwards Lifesciences Corp in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 176 | Section 10a, Agilent Technologies, Inc. reciprocity | DEF 14A | — | 0001193125-26-040286 | Agilent Technologies, Inc. names Edwards Lifesciences Corp in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 177 | Section 10a, DexCom, Inc. reciprocity | DEF 14A | — | 0001093557-26-000061 | DexCom, Inc. names Edwards Lifesciences Corp in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 178 | Section 10a, Hologic, Inc. reciprocity | DEF 14A | — | 0001140361-25-001287 | Hologic, Inc. names Edwards Lifesciences Corp in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 179 | Section 10a, Zimmer Biomet Holdings, Inc. reciprocity | DEF 14A | — | 0001193125-26-135661 | Zimmer Biomet Holdings, Inc. names Edwards Lifesciences Corp in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 180 | Section 10a, ResMed Inc. reciprocity | DEF 14A | — | 0000943819-25-000079 | ResMed Inc. names Edwards Lifesciences Corp in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 181 | Section 10a, The Cooper Companies, Inc. reciprocity | DEF 14A | — | 0001628280-26-011110 | The Cooper Companies, Inc. names Edwards Lifesciences Corp in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 182 | Section 10a, Intuitive Surgical, Inc. reciprocity | DEF 14A | — | 0001035267-26-000023 | Intuitive Surgical, Inc. names Edwards Lifesciences Corp in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 183 | Section 10a, Becton, Dickinson and Company reciprocity | DEF 14A | — | 0001628280-25-057846 | Becton, Dickinson and Company's most recent proxy was read; its disclosed peer group does not include Edwards Lifesciences Corp. Filing ↗ |
| 184 | Section 10a, Baxter International Inc. reciprocity | DEF 14A | — | 0001628280-26-020330 | Baxter International Inc. names Edwards Lifesciences Corp in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 185 | Section 10a, GE Healthcare Technologies Inc. reciprocity | DEF 14A | — | 0001932393-26-000021 | GE Healthcare Technologies Inc. names Edwards Lifesciences Corp in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 186 | Section 10a, IDEXX Laboratories, Inc. reciprocity | DEF 14A | — | 0000874716-26-000064 | IDEXX Laboratories, Inc. names Edwards Lifesciences Corp in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 187 | Section 10a, Boston Scientific Corporation reciprocity | DEF 14A | — | 0000885725-26-000025 | Boston Scientific Corporation names Edwards Lifesciences Corp in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 188 | Section 10a, Stryker Corporation reciprocity | DEF 14A | — | 0000310764-26-000013 | Stryker Corporation's most recent proxy was read; its disclosed peer group does not include Edwards Lifesciences Corp. Filing ↗ |